Purificación Martínez del Prado

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen

Miguel Martín, Aňa Lluch, Miguel Ángel Seguí et al. · Annals of Oncology · 2006 · 204 citations · Full text

Medicine, Oncology, Pharmacology +17

Risk-Adapted Treatment in Clinical Stage I Testicular Seminoma: The Third Spanish Germ Cell Cancer Group Study

Jorge Aparicio, Pablo Maroto, Xavier García del Muro et al. · Journal of Clinical Oncology · 2011 · 127 citations · Full text

Medicine, Oncology, Surgery +16

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17

First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients. Results of the On study

M.L. García de Paredes, F. del Moral González, Purificación Martínez del Prado et al. · Annals of Oncology · 2010 · 88 citations

Medicine, Neurology, Oncology +16